Division of Cardiology, Department of Internal Medicine, NHIS Ilsan Hospital, Goyang-si, Gyeonggi-do, South Korea; Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Yonsei University Health System, Seoul, South Korea.
Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Yonsei University Health System, Seoul, South Korea; Division of Cardiology, Department of Internal Medicine, Myungji Hospital, Goyang-si, Gyeonggi-do, South Korea.
JACC Cardiovasc Imaging. 2017 Apr;10(4):437-446. doi: 10.1016/j.jcmg.2016.04.013. Epub 2016 Oct 19.
The aim of this study was to explore the relationship between temporal changes in coronary plaque volume and the intensity of lipid-lowering treatments, utilizing coronary computed tomography angiography (CTA).
Coronary CTA has acceptable accuracy in terms of quantitative measurement of plaque volume. Although, coronary CTA is perhaps capable of identifying the differences in plaque volume progression according to the intensity of lipid lowering treatment, to date, few studies have examined this notion.
In this multicenter, observational study, the authors reviewed 467 patients who underwent serial coronary CTA with a scan period of more than 2 years (median 3.2 years [2.4 to 4.8]) apart, and whose laboratory data were available within 1 month of both the baseline and follow-up coronary CTA. Among them, 147 patients (comprising 336 vessels) with visible plaque were enrolled in this study. The authors performed quantitative assessment of coronary plaque in both. Patients who achieved a low-density lipoprotein cholesterol (LDL-C) with a cut off value below 70 mg/dl at follow-up were compared with those who did not.
Patients with LDL-C below 70 mg/dl displayed a significant attenuation in plaque progression as compared with those with follow-up LDL-C levels ≥70 mg/dl (12.7 ± 38.2 mm vs. 44.2 ± 73.6 mm, respectively; p = 0.014). In multivariate analysis, factors influencing plaque progression per year was follow-up LDL-C levels ≥70 mg/dl (beta 0.193; p = 0.021).
Strict LDL-C control appeared to significantly attenuate plaque volume progression based on noninvasive quantitative assessment by coronary CTA.
本研究旨在利用冠状动脉 CT 血管造影(CTA)探讨冠状动脉斑块体积随时间的变化与降脂治疗强度之间的关系。
冠状动脉 CTA 在斑块体积定量测量方面具有可接受的准确性。尽管如此,冠状动脉 CTA 或许能够根据降脂治疗强度识别斑块体积进展的差异,但迄今为止,很少有研究对此进行探讨。
在这项多中心观察性研究中,作者回顾了 467 例连续接受冠状动脉 CTA 检查的患者,两次扫描间隔时间超过 2 年(中位数为 3.2 年[2.4 至 4.8]),且在基线和随访冠状动脉 CTA 检查后 1 个月内均获得了实验室数据。其中,147 例(共 336 支血管)有可见斑块的患者纳入本研究。作者对这两组患者的冠状动脉斑块进行了定量评估。将随访时 LDL-C 低于 70mg/dl 的患者与 LDL-C 水平≥70mg/dl 的患者进行比较。
与 LDL-C 水平≥70mg/dl 的患者相比,LDL-C 低于 70mg/dl 的患者斑块进展明显减少(分别为 12.7±38.2mm 和 44.2±73.6mm;p=0.014)。多变量分析显示,每年斑块进展的影响因素为随访 LDL-C 水平≥70mg/dl(β 0.193;p=0.021)。
基于冠状动脉 CTA 的非侵入性定量评估,严格的 LDL-C 控制似乎可显著减缓斑块体积的进展。